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nnUK Dementia Research Institute, London, UKAbstract Introduction: Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are a
“Holy Grail” of AD research and intensively sought; however, there are no well-established plasma
markers.
Methods: A hypothesis-led plasma biomarker search was conducted in the context of international
multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL;
259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.
Results: Ten analytes showed significant intergroup differences. Logistic regression identified five
(FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and
CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI
(AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two
analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).
Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and
outcome prediction in AD and MCI. Further replication is needed before clinical translation.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Alzheimer’s disease; Biomarker; Plasma; Inflammation; Complement1. Introduction
Alzheimer’s disease (AD) is a complex neurodegenera-
tive disorder that develops gradually and progressively,
with symptoms progressing over time from mild forgetful-
ness to severe mental impairment. Early diagnosis is an
essential requirement for effective intervention but is chal-
lenging because of current reliance on clinical observation
and cognitive testing, with diagnosis confirmed postmortem
by demonstrating typical AD brain pathology. Biomarkers of
early disease might address this challenge and are thus an
urgent unmet need.
Currently, cerebrospinal fluid (CSF) levels of amyloid b
(Ab) fragments and hyperphosphorylated or total tau are
the most widely used biomarkers for AD [1,2]; however,
diagnostic accuracy varies between centers [3]. Further-
more, lumbar puncture is invasive and difficult to implement
in the presymptomatic elderly population. The accessibilityand practicability of obtaining peripheral blood to measure
disease biomarkers make this an attractive option for early
diagnosis and large-scale screening. Numerous discovery
studies for blood-based biomarkers of AD have been re-
ported, but validation and replication remain key challenges
and none has yet achieved clinical usefulness [4–7].
Promising candidates do exist, for example, plasma Ab42/
40 ratio and neurofilament light chain [8], but more work
is needed.
Considerable evidence implicates inflammation and
complement dysregulation in AD pathogenesis. Genome-
wide association studies demonstrated strong associations
between AD and common SNPs in the gene encoding the
complement regulator clusterin (CLU) [9]. A second
genome-wide association study replicated the CLU associ-
ation and identified association with an SNP in the CR1
gene, encoding complement receptor 1 (CR1) [10]. These
findings have been robustly replicated in diverse cohorts.
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inflammation, and complement as key pathways in AD
[11–13]. Other evidence implicating inflammation and
complement includes longitudinal studies demonstrating
that inflammation occurs years before AD onset [14,15],
and cross-sectional studies reporting increased inflamma-
tory markers in early AD [16]. Plasma markers of inflamma-
tion and complement dysregulation may therefore be useful
biomarkers of early AD. Indeed, complement proteins, reg-
ulators, and activation products were altered in AD plasma
and/or CSF [17], and in a systematic review of 21 discovery
or panel-based blood proteomic studies, complement was
the top implicated pathway across the studies [18].
The underpinning hypothesis of this study is that plasma
levels of complement proteins and other inflammatory bio-
markers differ between neurologically normal elderly con-
trols (CTL) and those with mild cognitive impairment
(MCI) and/or AD, between subjects with MCI and those
with AD, and between subjects with MCI destined to rapidly
progress to AD (progressors) and those who will not prog-
ress (nonprogressors). If proven, then the most informative
of these plasma biomarkers can be used to diagnose, stratify,
predict disease progression, and/or demonstrate response to
intervention in MCI and AD. Analytes were selected based
on biological evidence and published studies of inflamma-
tory/complement biomarkers in neurodegeneration. In the
discovery phase, we used singleplex and multiplex solid-
phase enzyme immunoassays to measure 53 proteins
comprising complement components, activation products
and regulators, cytokines and chemokines in a large cohort
comprising AD, MCI, and CTL samples. Proteins demon-
strating association with AD and/or MCI in this discovery
sample set were investigated further in two independent
replication cohorts.2. Methods
2.1. Study population
Discovery phase samples were from AddNeuroMed, a
cross-European cohort for biomarker discovery, detailed
elsewhere [19,20]. Informed consent was obtained
according to the Declaration of Helsinki (1991), and
protocols and procedures were approved by Institutional
Review Boards at each collection site. We used 720
plasma samples from the cohort: 262 AD, 199 MCI, and
259 CTL, selected based solely on availability of plasma
samples. The replication cohorts comprised (1) 867 plasma
samples (88 AD, 425 MCI, 347 CTL) from European
Medical Information Framework for Alzheimer’s Disease
Multimodal Biomarker Discovery (EMIF-AD MBD), a
cross-European biomarker discovery cohort [21]; (2) 427
plasma samples (105 AD, 69 MCI, 253 CTL) from Mauds-
ley Biomedical Research Centre Dementia Case Registry
(DCR) [22]. In both cases, samples were selected based
solely on availability of plasma; plasma was not collectedfrom all individuals in the cohorts and stocks had been ex-
hausted for others. Diagnostic categories were created using
similar algorithms in the discovery and replication cohorts
[19–22]. In all cohorts, the definition for CTL was a
normal performance on neuropsychological assessment
(within 1.5 SD of the average for age, gender, and
education). Diagnosis of MCI was made according to the
criteria of Petersen [23], and AD-type dementia was diag-
nosed using the National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association criteria [24].
Patient data available differed between the cohorts; there-
fore, a minimal clinical data set was collected and harmo-
nized as described [21]; this data set comprised 1)
demographics: age, gender, education; 2) clinical informa-
tion: diagnosis, medication use, comorbidities, family
history of dementia, functional impairment rating; 3) cogni-
tive data: Mini–Mental State Examination, neuropsycholog-
ical testing. Imaging data and CSF samples were not
available for a majority of cases included in the cohorts
and so could not be included in the analyses; however, this
was not considered an issue given that the aim of the work
was to identify plasma markers that correlated with clinical
disease status.2.2. Discovery phase assays
In the discovery phase, 53 plasma analytes were measured
using commercial and in-house singleplex and multiplex as-
says on all available samples in duplicate from AddNeur-
oMed. Plasma clusterin, soluble complement receptor 2,
C-reactive protein (CRP), colony-stimulating factor 1
(CSF1), and interleukin-23 (IL-23) were determined using
commercially available enzyme-linked immunosorbent as-
says (clusterin, CRP, CSF1, and IL-23 from R&D systems
(Abingdon, UK; cat# DY5874, DY1707, DY216, and
DY5265 B) and soluble complement receptor 2 from Sino
Biological (Beijing, China; cat# SEKA10811); protocols
were as recommended by the manufacturers. Plasma soluble
complement receptor 1 (sCR1), C1-inhibitor (C1inh), C5,
C9, C1q, factor H-related protein 4 (FHR4), factor H (FH)
Y402, and H402 variants were determined using optimized
antibody pairs in in-house enzyme-linked immunosorbent as-
says as described [25]. Ten complement biomarkers were
measured using customized V-plex electrochemilumines-
cence (ECL) immunoassays (MSD; Rockville, Maryland);
antibody pairswere developed and optimized in-house.Multi-
plex 1 comprised abundant analytesC3,C4, factorB (FB), FH,
and factor I (FI).Multiplex 2 comprised low-concentration an-
alytes factor D (FD); the activation fragments Bb, C3a, and
iC3b; and the terminal complement complex (TCC). A cali-
bration curve comprising five-fold dilutions of a mixture of
protein standards was run in duplicate on each plate. ECL
signal was measured on the MESO QuickPlex SQ 120 reader
(MSD). Data acquisition and analysis was performed using
MSD software Discovery workbench 4.0.
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K15054D) was used to measure cytokines/chemokines.
The kit comprises three 10-plex panels: V-plex Proinflam-
matory Panel 1 measures interferon g, interleukin (IL)-1b,
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor
necrosis factor (TNF)-a in samples diluted 1:2 in proprietary
buffer; V-plex cytokine panel 1 measures granulocyte-
macrophage colony-stimulating factor, IL-1a, IL-5, IL-7,
IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-b, and vascular
endothelial growth factor–A in samples diluted 1:4; V-
plex chemokine panel 1 measures eotaxin-1, macrophage
inflammatory protein (MIP)-1b, eotaxin-3, thymus- and
activation-regulated chemokine (TARC; CCL17), inter-
feron-g-inducible protein (IP)-10, MIP-1a, IL-8, MCP-1,
macrophage-derived chemokine, and MCP-4 in samples
diluted 1:4. All assays were performed according to manu-
facturer’s instructions using ECL detection as mentioned
previously. Intra-assay and interassay limits for coefficients
of variation (CV) were set at 25%, and data for samples with
a CV above this were not included in the analysis.
2.3. Replication phase assays
The analytes selected from the discovery phase for repli-
cation were sCR1, FB, FH, MCP-1, and eotaxin-1; FI, TCC,
clusterin, and C4 were also included to replicate previously
reported association of these biomarkers with MCI progres-
sion [26], not tested in AddNeuroMed cohort.
MSD U-PLEX custom multiplexing was used in replica-
tion phase to build bespoke panels. Plasma levels of low
abundance analytes sCR1, MCP-1, eotaxin-1, and TCC
were measured in one panel with samples diluted 1:2;
plasma levels of high abundance analytes FB, FH, FI, clus-
terin, and C4 were measured in a second panel with samples
diluted 1:2000. Assays were performed according to the
manufacturer’s instructions using ECL detection. Both
panels were run on all EMIF-AD MBD and DCR samples
in duplicate. Intra-assay and interassay limits for CV were
set at 25% as above.
2.4. Statistical analysis
All statistical tests and analyses were performed with R
software, including ggplot2, caret, and pROC packages. In
all cases, P , .05 was considered statistically significant.
2.4.1. Individual analytes
Protein concentrations were determined automatically
from standard curves plotted using GraphPad Prism5. Values
were adjusted for recruitment center and plasma storage time
as described [27] using a generalized linear regression model.
All subsequent analyses were performed on generalized
linear regression model–adjusted data and log-transformed
to achieve normal distribution. In the discovery phase, associ-
ation of individual analytes with disease status was tested us-
ing the Kruskal-Wallis test. Pairwise comparisons were thenperformed using the Dunn test with Bonferroni correction.
For 12 analytes (eotaxin-3, granulocyte-macrophage col-
ony-stimulating factor, IL-1b, IL-2, IL-4, IL-5, IL-7, IL-10,
IL12p70, IL-13, MIP-1a, TNFb), many samples were below
assay detection limits; thesewere analyzed as binary variables
(positive or negative) and tested for association with disease
status by chi-square test.
2.4.2. Identification of optimal analyte sets
Stepwise logistic regression (SLR) was used to find the
analyte set that optimally distinguished between diagnostic
groups: CTL versus AD, CTL versus MCI, MCI versus
AD. Demographic covariates age, gender, and apolipopro-
tein E (APOE) genotype were controlled for and included
in models as potential predictors. For each comparison,
the data set was randomly split into training (80%) and
validation (20%) sets. The training set was used to select
variables and fit the model which was then tested on the
validation set using receiver operating curve (ROC) anal-
ysis. The models developed for AD versus CTL and MCI
versus AD were tested in the replication cohorts using
ROC analysis.
2.4.3. Markers of disease progression
Data on MCI progression to AD were only available in a
subset of the EMIF-ADMBD; in this case, SLR was used to
find the analyte set that best distinguished individuals who
subsequently progressed from MCI to AD from nonprogres-
sors. Because the MCI conversion group was relatively
small, stepwise selection was performed on the complete
data set, followed by ROC analysis with leave-one-out
cross-validation. To avoid overfitting, 500 replications of
stepwise models were performed on random data subsets,
each comprising a training set (80%) for selection and a vali-
dation set (20%) for model testing, and ROC analysis per-
formed for each replication. The variables most often
selected and significant were identified.3. Results
3.1. Individual analytes differ between discovery set
groups
Of the 53 plasma proteins measured in the discovery set,
10 demonstrated significant differences between clinical
groups (Table 1). Pairwise comparisons (Dunn test with
Bonferroni correction) showed (1) for AD versus CTL,
increased C4 and eotaxin-1, decreased sCR1, C5, and
CRP; (2) for MCI versus CTL, increased FH, C3, and
MCP-1, decreased C5 and MIP-1b; (3) for AD versus
MCI, increased eotaxin-1 and MIP-1b, decreased FI, C3,
CRP, MCP-1 (Table 1; Fig. 1). Of the 12 MSD cytokine/che-
mokine panel analytes analyzed categorically, none showed
significant differences between clinical groups.
Table 1
Ten analytes associated with clinical state in the discovery phase
Analyte
Mean 6 SD
CTL (n 5 259)
Mean 6 SD
MCI (n 5 199)
Mean 6 SD
AD (n 5 262)
P value
KW test
P value
AD vs. CTL
P value
AD vs. MCI
P value
MCI vs. CTL
FH (mg/ml) 241.5 (56.4) 262.7 (71.8) 258.2 (73.0) .01 ns ns .004
FI (mg/ml) 31.5 (7.0) 32.2 (6.9) 31.0 (7.5) .049 ns .03 ns
sCR1 (ng/ml) 11.52 (3.03) 11.43 (3.10) 10.88 (3.01) .043 .03 ns ns
C3 (mg/ml) 1042.7 (553.4) 1105.0 (377.4) 1004.2 (435.4) ,.0001 ns .0001 .001
C4 (mg/ml) 351.6 (129.6) 370.8 (136.2) 386.1 (159.3) .01 .01 ns ns
C5 (mg/ml) 84.9 (16.2) 81.0 (14.7) 79.8 (14.7) .001 .0004 ns .03
CRP (ng/ml) 996.8 (1145.6) 841.3 (711.1) 761.1 (810.5) .007 .01 .09 ns
MCP-1 (pg/ml) 63.1 (22.5) 68.5 (24.5) 63.0 (20.4) .009 ns .006 .002
Eotaxin-1 (pg/ml) 141.6 (65.0) 143.3 (66.2) 162.5 (78.7) ,.0001 ,.0001 ,.0001 ns
MIP-1b (pg/ml) 58.9 (29.2) 58.1 (55.2) 63.1 (56.2) .007 ns .006 .002
Abbreviations: AD, Alzheimer’s disease; CRP, C-reactive protein; CTL, control; KW, Kruskal-Wallis; MCI, mild cognitive impairment; ns, not significant;
SD, standard deviation.
NOTE. Ten analytes showed statistically significant differences in concentration between clinical groups in the discovery phase. The table shows means and
standard deviations, KW test P value, and Dunn test P values for each analyte.
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3.2.1. AD from CTL
Stepwise selection demonstrated strong interdependence
between some analytes and revealed other analytes that
significantly and independently contributed to distinguish-
ing clinical groups. SLR modeling was used to identify the
most predictive set of analytes. A model combining FB,
FH, sCR1, MCP-1, and eotaxin-1 with covariates age and
APOε4 status best differentiated AD versus CTL. FH and
eotaxin-1 were higher and FB, CR1, and MCP-1 were lower
in AD compared to CTL. Diagnostic accuracy in distin-
guishing CTL from AD was moderate (AUC 0.79); 77% of
samples were predicted correctly with 84% sensitivity and
70% specificity (Fig. 2A; Table 2). This model was tested
in the replication cohorts. In EMIF-AD MBD, comprising
867 plasma samples (88 AD, 425 MCI, 347 CTL), the model
strongly replicated (AD vs. CTL; AUC 0.81), correctly pre-
dicting 76% of samples with 73% sensitivity and 77% spec-
ificity. In DCR, comprising 427 samples (105 AD, 69 MCI,
253 CTL), the model performed poorly (AD vs. CTL; AUC
0.58).
3.2.2. AD from MCI
A model combining sCR1, MCP-1, and eotaxin-1 with
age and APOε4 optimally differentiated AD and MCI
(AUC 0.74), correctly predicting 71% of samples with
75% sensitivity and 66% specificity (Fig. 2B; Table 2). FH
and eotaxin-1 were higher and FB, sCR1, and MCP-1
were lower in AD compared to MCI samples. The model
replicated in EMIF-ADMBD (AUC 0.67), correctly predict-
ing 61% of samples with 71% sensitivity and 59% speci-
ficity. In DCR samples, the model performed poorly (AUC
0.56).3.2.3. MCI from CTL
The optimal model to differentiate MCI from CTL
comprised 15 analytes, each providing weak and indepen-dent predictive value. Smaller analyte sets were poor predic-
tors (details not shown). We concluded that there was no
reliable and practicable biomarker set from the analytes
measured that distinguished MCI and CTL.
3.2.4. MCI progressors from nonprogressors
Baseline samples from 285 individuals with MCI who
had either progressed to AD when reassessed 12 months
later (progressors; 55) or had remained stable over this
period (nonprogressors; 230) were compared in EMIF-AD
MBD. Of the nine analytes measured, only two, FB (higher
in progressors) and FH (lower in progressors), were signifi-
cantly different between progressors and nonprogressors. A
model combining these two analytes with age, the only sig-
nificant covariable, was moderately predictive (AUC 0.71);
67% of samples correctly predicted, sensitivity 71%, speci-
ficity 67% (Table 3). In the 500 replications of stepwise
models, age and FH were always selected and significant
499 times, FB was selected 414 times and significant 309
times. No other analyte was selected more than 67 times.
The average AUC for the 500 replications was 0.69 (SD
0.09).4. Discussion
A plasma biomarker or biomarker set that aids early diag-
nosis, stratification, prediction of disease course, or moni-
toring response to therapy in AD is a major unmet need.
Numerous studies have sought plasma biomarkers relevant
to AD, and many putative plasma protein biomarkers have
been proposed (reviewed in the study by Baird et al. [28]);
however, none has been robustly replicated. Currently, clini-
cians rely on neuropsychological testing, a time-consuming
tool, to diagnose MCI and AD, with confirmation requiring
either expensive neuroimaging (MRI or PET scanning) or
invasive lumbar puncture to measure CSF markers of amy-
loid or tau pathology. These methods are not suitable either
for high-volume screening of presymptomatic individuals,
Fig. 1. Ten biomarkers associated with diagnosis in the discovery phase. Boxplots for the 10 biomarkers which demonstrated significant differences in con-
centrations between diagnostic groups (Kruskal-Wallis). The P values shown are from the Dunn test with Bonferroni correction for pairwise comparisons;
bars indicate significant differences. For graphical convenience and better visualization, high outliers were removed from the boxplots, although all are included
in the Kruskal-Wallis analysis. Abbreviation: CRP, C-reactive protein.
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required in assessing response to interventions. Biomarkers
informative in CSF are currently difficult to measure inplasma in the routine context [29]. Recent technological ad-
vances have improved assay sensitivity, delivering ultrasen-
sitive assays capable of measuring specific amyloid markers
Fig. 2. Receiver operating characteristic (ROC) curves for models distin-
guishing clinical state or predicting progression. ROC curves were gener-
ated representing models which best differentiated AD from controls (A)
or AD from MCI (B) in the discovery phase and predicted progression or
nonprogression in the EMIF cohort (C). In each case, the area under the
curve (AUC) for the selected model was calculated, and compared to that
for the significant covariables alone, age 1 APOE ε4 in (A) and (B), age
alone in (C). (A) Shows that a model including FB, FH, sCR1, MCP-1,
and eotaxin-1, along with the covariables age and APOE genotype, differen-
tiated AD and CTL with a predictive power (AUC) of 0.79 (red line), signif-
icantly better than the covariables alone (AUC 0.65; blue line). (B) Shows
that a model including sCR1, MCP-1, and eotaxin-1, along with the covari-
ables age and APOE genotype, differentiated AD and MCI with AUC of
0.74 (red line), significantly better than the covariables alone (AUC 0.63;
blue line). (C) Shows that a model including FB and FH along with age
as covariable differentiated MCI progressors and nonprogressors with
AUC of 0.71 (red line). The predictive power was significantly greater
than that obtained using the covariable alone (AUC 0.66; blue line). Abbre-
viations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CTL, control;
MCI, mild cognitive impairment.
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ultrasensitive assays require expensive purpose-built equip-
ment beyond routine laboratory capacity and currently too
costly for large-scale screening.
In this study, we set out to identify plasma analyte sets,
measurable using simple multiplex enzyme-linked immuno-
sorbent assay, that differentiated AD, MCI, and CTL groups.
We took as a starting point the powerful multisource evi-
dence that inflammation and complement dysregulation
were important components of AD pathogenesis [13–17].
In the discovery phase, we used multiplex and singleplex
immunoassays to measure 53 proteins relevant to
inflammation and complement dysregulation in a large,
well-validated cohort, and identify proteins and/or protein
sets associated with AD and/or MCI clinical diagnosis.
Ten of the 53 proteins were significantly different between
groups of different clinical status; a heterogeneous group
of analytes including three complement components (C3,
C4, C5), two complement regulators (FH, FI), a soluble
form of a complement receptor (sCR1), a classical marker
of inflammation (CRP), and three chemokines (eotaxin-1,
MCP-1, and MIP-1b). Stepwise selection demonstrated
strong interdependence between some analytes, anticipated
given that all were selected for relevance to complement
and/or inflammation; however, several analytes significantly
and independently contributed to distinguishing between
clinical groups. To identify the most predictive set, models
that tested all combinations of analytes and covariables
were generated. The best model for AD versus CTL,
including analytes sCR1, FB, FH, eotaxin-1, and MCP-1,
with covariables age and APOE status, showed an AUC of
0.79 in the discovery cohort, considered “highly predictive”
[32]. The best model for AD versus MCI, including analytes
sCR1, eotaxin-1, and MCP-1 with covariables age and
APOE status, yielded an AUC of 0.74, considered “moder-
ately predictive” [32].
Both models were tested in two independent replication
cohorts. In the larger of these, EMIF-AD MBD (comprising
867 samples: 88 AD, 425 MCI, 347 CTL), both models
replicated, AD versus CTL strongly (AUC 0.81), and AD
versus MCI moderately (AUC 0.67). In the smaller DCR
cohort (105 AD, 69 MCI, 253 CTL), neither model repli-
cated well (AUC 0.58 for AD vs. CTL; 0.56 for AD vs.
MCI). The reasons for failure to replicate in the DCR cohort
are unclear; however, this is a relatively small sample set,
60% of which are CTL samples. The strong replication of
both models in the larger multicenter EMIF-AD MBD
cohort provokes us to suggest that the analytes identified
here, perhaps with other promising biomarkers, might pro-
vide a basis for a focused, relatively simple and inexpensive
plasma multiplex test that could aid diagnosis. Further
research in large, well-characterized cohorts to replicate,
validate, and extend these findings is needed to deliver a reli-
able screening tool.
With the exception of FB, each of the analytes selected
in the models has previously been associated with AD.
Table 2
Multivariate models for distinguishing between diagnostic groups
Predictor
AD vs. CTL AD vs. MCI
LogOR (95% CI) P value LogOR (95% CI) P value
Intercept 213.49 (227.16; 0.17) .05 23.62 (27.89; 0.65) .10
Age 0.07 (0.04; 0.12) .00005 0.06 (0.02; 0.10) .002
1 APOE ε4 0.74 (0.22; 1.25) .005 0.41 (20.10; 0.92) .12
2 APOE ε4 2.03 (1.0; 3.05) .0001 1.99 (0.86; 3.13) .0006
Eotaxin-1 1.56 (0.78; 2.35) .00009 1.74 (0.97; 2.52) .00001
MCP-1 21.31 (22.21; 0.40) .0005 21.91 (22.82; 21.01) .00003
sCR1 20.90 (21.85; 0.06) .067 21.36 (22.30; 20.41) .005
FH 2.85 (1.42; 4.27) .00009 n/a n/a
FB 22.33 (23.60; 21.06) .0003 n/a n/a
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CTL, control; MCI, mild cognitive impairment; logOR (95% CI), log odds ratio of the
predictor and their 95% confidence interval; Intercept, log odds ratio if the predictors are equal to 0; 1 APOE E4/2 APOE E4: log odds ratio of possessing 1 or 2
ε4 alleles compared to possessing no ε4 allele; n/a, predictors not included in the given model.
NOTE. The table summarizes the selected logistic regression models derived from the AddNeuroMed discovery cohort, AD versus CTL in the left panel, AD
versus MCI in the right panel.
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measured in AD plasma previously but was reported higher
in CSF in AD versus CTL [33]. FH (increased in AD vs.
CTL) was reported higher in AD plasma in several studies
[4,34,35], although some reported no difference between
clinical groups [36]. Eotaxin-1 (higher in AD plasma vs.
CTL and MCI) and MCP-1 (lower in AD plasma vs. CTL
and MCI), both C–C chemokine family members, were re-
ported as plasma markers of AD status in several studies
[37–42]; elevated MCP-1 and eotaxin-1 correlated with
greater memory impairment in MCI/AD [43].
Several studies have reported plasma biomarkers predic-
tive of MCI progression to AD. An 18-analyte biomarker
signature dominated by cytokines/chemokines predicted
progression within 5 years with 81% accuracy [44]. A 60-
analyte set was predictive of MCI progression to AD with
79% accuracy [45], and a 10-analyte panel, including com-
plement and inflammatory proteins, predicted MCI progres-
sion to AD with 87% accuracy [22]. Our published study
identified a model comprising three analytes, FI, TCC, and
clusterin that, with APOε4 status, predicted progression
(AUC 0.86) [26]. To date, none of these findings haveTable 3
Multivariate model for distinguishing between MCI converters and
nonconverters
Predictor LogOR (95% CI) P value
Intercept 14.13 (25.77; 34.01) .16
Age 0.08 (0.04; 0.13) .00019
FH 24.15 (26.24; 22.05) .00011
FB 2.66 (0.72; 4.60) .0072
Abbreviations: MCI, mild cognitive impairment; logOR (95% CI), log
odds ratio of the predictor and the 95% confidence interval; Intercept, log
odds ratio if the predictors are equal to 0.
NOTE. The table summarizes the selected logistic regression model
derived from informative samples in the EMIF cohort for MCI converters
versus nonconverters.been independently replicated. Of the cohorts available to
us, only EMIF-AD MBD included data on progression of
MCI cases to AD; 19% of informative MCI cases had pro-
gressed to AD a year after sampling. Of the 10 analytes
measured, two were significantly different; FB levels were
higher and FH lower in MCI progressors versus nonprogres-
sors. These two biomarkers together with age (the only sig-
nificant covariable) predicted MCI conversion with AUC
0.71. Notably, FB is a key enzyme in the complement ampli-
fication loop while FH is the critical loop regulator;
increased FB and decreased FH seen in progressors would
favor amplification, suggesting that amplification loop dys-
regulation might predispose to progression. We were unable
to replicate this finding in other cohorts as data on conver-
sion were not available. Although the model reported for
predicting MCI conversion differs from our previous report
[26], both identified markers of complement activation/regu-
lation, implying that complement dysregulation is a critical
predictor of progression. This finding resonates with preclin-
ical data suggesting that complement and microglial activa-
tion play important roles as mediators of neurotoxicity in
AD [46]. Further research to replicate and validate markers
of complement dysregulation as predictors of progression is
required.
There are limitations to the present study. The cohorts
were collected across a wide range of centers and without
stringent attention to sampling, separation, and storage pro-
tocols that are important for complement and other immunity
assays; however, despite this suboptimal aspect, character-
istic of real-world sample collections, strongly predictive
marker sets emerged, increasing the likelihood of utility in
clinical practice. For several analytes, the commercial cyto-
kine/chemokine platform was insufficiently sensitive for
detection in plasma, highlighting the need for better assays.
For most subjects in the cohorts analyzed, imaging data
and/or CSF samples were not available and thus could not
be included in the analysis. Despite these limitations, we
A.R. Morgan et al. / Alzheimer’s & Dementia 15 (2019) 776-787784discovered and replicated evidence that neuroinflammation
and complement dysregulation are pathological drivers in
AD and thus potential therapeutic targets. Several observa-
tional studies have reported that long-term use of nonste-
roidal anti-inflammatory drugs is associated with reduced
risk of dementia [47,48]; however, randomized controlled
trials and systematic reviews found little or no benefit of
nonsteroidal anti-inflammatory drugs [49,50]. Perhaps,
interventions in these latter studies were commenced too
late to confer benefit. Inflammatory biomarkers to stratify
and select patients for targeted early intervention might
benefit future trials of anti-inflammatory interventions. Tar-
geting complement dysregulation is, as yet, untested in
AD. Although current anticomplement drugs are tailored
for ultrarare diseases, numerous new drugs are progressing
to the clinic, including for therapy of common inflammatory
diseases, for example, age-related macular degeneration
[51]. Anticomplement drugs designed to access brain and tar-
geted to preclinical or early MCI patients identified and
selected using markers of complement dysregulation may
offer a new pathway to prevention of AD [52].Acknowledgments
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1. Systematic review: The authors reviewed the current
literature using traditional (e.g., Google Scholar;
PubMed) sources to identify published studies utiliz-
ing inflammation-relevant plasma biomarkers, in
particular complement markers, for diagnosis, stag-
ing, or risk prediction of Alzheimer’s disease. They
noted the dearth of replicated plasma biomarkers and
small sample size in many published studies.
2. Interpretation: Our findings identify sets of inflam-
matory biomarkers in plasma that distinguish clinical
subgroups (controls: mild cognitive impairment;
Alzheimer’s disease) in a large multicenter cohort;
these replicate in an independent cohort. Markers
predictive of progression were also identified in the
latter cohort.
3. Future directions: The findings require further repli-
cation in additional and larger independent cohorts,
before development as a clinically viable multi-
plexed test for diagnosis and patient stratification.
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